Positive Financials Along With Promising Clinical Results – Coya Therapeutics

Howard Berman, Ph.D., CEO & Chairman of the Board of Coya Therapeutics, Inc. COYA, was recently a guest on Benzinga’s All Access.

Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells, called Tregs. Tregs are a subset of T cells – a type of white blood cell – that function to maintain homeostasis and prevent autoimmunity.

The company is currently developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Mr. Berman shared some exciting news surrounding the development of its novel therapies. 

Watch the full interview here:

Featured photo by Hans Reniers on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.